Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models"

Science

Volumn 340, Issue 6135, 2013, Pages 924-

  Tesseur, Ina ^a,b   Lo, Adrian C ^c   Roberfroid, Anouk ^a,b   Dietvorst, Sofie ^a   Van Broeck, Bianca ^d   Borgers, Marianne ^d   Gijsen, Harrie ^d   Moechars, Diederik ^d   Mercken, Marc ^d   Kemp, John ^d   D'Hooge, Rudi ^c   De Strooper, Bart ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BETA CYCLODEXTRIN SULFOBUTYL ETHER; BEXAROTENE; TETRALIN DERIVATIVE;

ALZHEIMER DISEASE; CLINICAL TRIAL (TOPIC); COGNITION; DRUG FORMULATION; GROOMING; MOUSE; NONHUMAN; NOTE; PASSIVE AVOIDANCE; PRIORITY JOURNAL; RIGHT HEMISPHERE; ANIMAL; BRAIN; MALE; METABOLISM;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; APOLIPOPROTEINS E; BRAIN; MALE; TETRAHYDRONAPHTHALENES;

MLCS; MLOWN;

EID: 84877950101     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1233937     Document Type: Note

References (5)

1. A. D. Roses, A. M. Saunders, Curr. Opin. Biotechnol. 5, 663 (1994).
2. P. E. Cramer et al., Science 335, 1503 (2012).
3. R. Radde et al., EMBO Rep. 7, 940 (2006).
4. Eisai Manufacturing Ltd. (EML), Targretin information; www.drugs.com/uk/targretin-capsules-1302.html (2009).
5. FDA, Drug approval package, Targretin; www.accessdata. fda.gov/drugsatfda-docs/nda/99/21055-Targretin.cfm (1999).